22 April 2025
- Multi-modality Topical Wound Oxygen (TWO2) therapy to be included in NHS supply chain framework agreement for 2025
- AOTI, Inc. (AIM: AOTI), a medical technology group focused on durable healing of wounds and prevention of amputations, announces inclusion of its TWO2 therapy in the framework agreement for Advanced Wound Care 2025
The AOTI Group, a medical technology company, has announced that its Two2 therapy will be included in the NHS supply chain framework agreement for Advanced Wound Care 2025. This inclusion is the result of a new health economic study published in the Journal of Diabetic Complications, which demonstrated that the therapy would significantly lower overall diabetic foot care costs for the NHS in England.
Significant Cost Savings for NHS
The health economic study showed that the adoption of AOTI’s unique Two2 therapy within the NHS would lead to significant cost savings. According to the study, the therapy would increase Quality Adjusted Life Years (QALYs) and improve outcomes relative to standard care, while lowering costs by an estimated £5,038 per patient, or 16%, over the course of two years.
| Estimated Cost Savings | £5,038 per patient | 16% reduction in costs |
| Over 2 years | for patients | relative to standard care |
The study used a comprehensive health economic model to estimate the cost effectiveness of Two2 therapy, taking into account the durable healing outcomes demonstrated in the pivotal Two2 Randomised Control Trial (RCT) and UK healthcare cost norms.
Improved Outcomes for Patients
In addition to the cost savings, the study also demonstrated that the adoption of Two2 therapy would lead to improved outcomes for patients. The therapy has been shown to significantly reduce wound recurrence, hospitalisations, and amputations, all of which translate to improved quality of life for patients living with non-healing foot ulcers.
“It is exciting to see acknowledgement of the clinical and health economic benefits delivered by our unique cyclical-pressure Two2 therapy with its inclusion in the new framework agreement for Advanced Wound Care,” said Dr. Mike Griffiths, CEO and President of AOTI. “Once implemented, patients across England will have easier access to our proven limb-saving outcomes, and the NHS can start to realise substantial cost savings.”
NHS Supply Chain Framework Agreements
NHS supply chain framework agreements enable NHS trusts and healthcare organisations to procure goods and services. They provide a single route to market for suppliers, simplify procurement, and aim to deliver cost savings and efficiency while maintaining high clinical standards. The inclusion of Two2 therapy in the framework agreement for Advanced Wound Care 2025 demonstrates the NHS’s commitment to providing high-quality care while reducing costs. The agreement is expected to become effective on 1st September 2025.
About AOTI, Inc.
AOTI, Inc. is a medical technology group focused on the durable healing of wounds and the prevention of amputations. The company has developed a range of innovative therapies, including its unique Two2 therapy, which has been shown to significantly reduce wound recurrence, hospitalisations, and amputations.
news is a contributor at Toe Hurts. We are committed to providing well-researched, accurate, and valuable content to our readers.
